Sort   by:  
 Page size 
ProteomicsMezigdomide is effective alone and in combination with Menin inhibition in Acute Myeloid Leukemia
Small molecules that target the MENIN-KMT2A protein-protein interaction (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. ...
ORGANISM(S): Homo sapiens (Human) 
2024-02-15 | PXD041737 | Pride
Menin-kmt2a Menin inhibitor Acute myeloid leukemia Mezigdomide Ikaros 
ProteomicsMezigdomide is effective alone and in combination with Menin inhibition in Acute Myeloid Leukemia
Small molecules that target the MENIN-KMT2A protein-protein interaction (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. ...
ORGANISM(S): Homo sapiens (Human) 
2024-02-15 | PXD041735 | Pride
Menin-kmt2a Menin inhibitor Acute myeloid leukemia Mezigdomide Ikaros 
UnknownMezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma.
Not available
S-EPMC10969776 | biostudies-literature
UnknownMezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Not available
S-EPMC11033588 | biostudies-literature
UnknownModel based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.
Not available
S-EPMC10583261 | biostudies-literature
GenomicsMezigdomide is effective alone and in combination with Menin inhibition in pre-clinical models of KMT2A-r and NPM1c AML
Mezigdomide is effective alone and in combination with Menin inhibition in pre-clinical models of KMT2A-r and NPM1c AML
PRJNA970400 | ENA
TranscriptomicsMezigdomide is effective alone and in combination with Menin inhibition in pre-clinical models of KMT2A-r and NPM1c AML
To compare gene expression changes following treatment with two CELMoDs (cereblon E3 ligase modulators) in a Lysine Methyltransferase 2A-rearranged (KMT2A-r) acute myeloid leukemia cell line, we compared gene expression changes after 72 hour of treatment with Iberdomide/CC-220 and Mezigdomide/CC-924...
ORGANISM(S): Homo sapiens 
2024-02-20 | GSE232007 | GEO
GenomicsMezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [scATAC-seq]
Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [scATAC-seq]
PRJNA1287466 | ENA
GenomicsMezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [RNA-seq]
Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [RNA-seq]
PRJNA1287471 | ENA
GenomicsMezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [scRNA-seq]
Mezigdomide reverses T cell exhaustion through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways [scRNA-seq]
PRJNA1287469 | ENA
Sort   by:  
 Page size